Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study
Simone Parisi,
Andrea Becciolini,
Bernardo D,
Alberto Lo Gullo,
Olga Addimanda,
Mirco Magnani,
Massimo Reta,
Romina Andracco,
Natalia Mansueto,
Patrizia Del Medico,
Rosalba Caccavale,
Marino Paroli,
Maddalena Larosa,
Gerolamo Bianchi,
Dario Camellino,
Bernd Raffeiner,
Valeria Nucera,
Aurora Ianniello,
Cecilia Giampietro,
Francesca Ometto,
Marta Priora,
Aldo Biagio Molica Colella,
Elena Bravi,
Ilaria Platè,
Eugenio Arrigoni,
Viviana Ravagnani,
Alessandra Bezzi,
Fabio Mascella,
Maria Cristina Focherini,
Alessia Fiorenza,
Guido Rovera,
Rosetta Vitetta,
Palma Scolieri,
Vincenzo Bruzzese,
Alessandro Volpe,
Riccardo Bixio,
Antonio Marchetta,
Federica Lumetti,
Antonella Farina,
Simone Bernardi,
Francesco Girelli,
Elisa Visalli,
Giorgio Amato,
Francesco De Lucia,
Ylenia Dal Bosco,
Roberta Foti,
Rosario Foti,
Francesca Serale,
Francesco Cipollone,
Myriam Di Penta,
Emanuela Sabatini,
Eleonora Celletti,
Veronica Franchina,
Francesco Molica Colella,
Giulio Ferrero,
Gilda Sandri,
Dilia Giuggioli,
Maria Chiara Ditto,
Enrico Fusaro,
Giuditta Adorni,
Eleonora Di Donato,
Daniele Santilli,
Gianluca Lucchini,
Alarico Ariani
Therapeutic Advances in Musculoskeletal Disease
Published online on April 29, 2026
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by musculoskeletal and cutaneous involvement. While TNF inhibitors (TNFi) are commonly used as first-line biologic therapies, treatment failure is frequent. IL-23 ...